Filing Details

Accession Number:
0001225208-11-004558
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-02-02 14:53:40
Reporting Period:
2011-02-01
Filing Date:
2011-02-02
Accepted Time:
2011-02-02 14:53:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1405197 Talecris Biotherapeutics Holdings Corp. TLCR Pharmaceutical Preparations (2834) 202533768
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472129 Jr R Stephen Petteway 4101 Research Commons
79 T.w. Alexander Drive
Research Triangle Park NC 27709
Executive Vp, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-02-01 20,000 $1.39 65,198 No 4 M Direct
Common Stock Disposition 2011-02-01 25,000 $24.37 40,198 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options (right to buy) Disposition 2011-02-01 20,000 $1.39 20,000 $1.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
249,040 2006-04-01 2015-11-10 No 4 M Direct
Footnotes
  1. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2010.
  2. The number of shares reported includes restricted share units representing the right to receive 9,210 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.26 to $24.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The option is fully vested and immediately exercisable.